TY - JOUR T1 - An update on statistical modeling for quality risk assessment of clinical trials JF - medRxiv DO - 10.1101/2021.07.12.21260214 SP - 2021.07.12.21260214 AU - Björn Koneswarakantha AU - Timothé Ménard Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/11/2021.07.12.21260214.abstract N2 - Background As investigator site audits have largely been conducted remotely during the COVID-19 pandemic, remote quality monitoring has gained some momentum. To further facilitate the conduct of remote Quality Assurance (QA) activities for clinical trials, we developed new quality indicators, building on a previously published statistical modelling methodology.Methods We modeled the risk of having an audit or inspection finding using historical audits and inspections data from 2011 - 2019. We used logistic regression to model finding risk for 4 clinical impact factor (CIF) categories: Safety Reporting, Data Integrity, Consent and Protecting Endpoints.Results We could identify 15 interpretable factors influencing audit finding risk of 4 out of 5 findings. They can be used to realistically predict differences in risk between 25 and 41% for different sites which suffices to rank sites by finding risk.Conclusion Continuous surveillance of the identified risk factors and resulting risk estimates could be used to complement remote QA strategies for clinical trials and help to manage audit targets and audit focus also in post-pandemic times.Study highlights / Key pointsWhat is the current knowledge on the topic?Remote quality monitoring has gained momentum during the COVID-19 pandemic, e.g. for investigator site audits. It required additional efforts on both ends for document retrieval and generating reports. Thus, adapting risk-based strategies to narrow audit focus and to improve audit target selection has become a necessity.What question did this study address?We correlated past audit and inspection findings with operational site data to identify risk factors for specific finding categories, using logistic regression.What does this study add to our knowledge?We could identify 15 interpretable factors influencing audit finding risk of 4 out of 5 categories. They could be used to realistically predict differences in risk between 25 and 41% for different sites which suffices to rank sites by finding risk.How might this change drug discovery, development, and/or therapeutics?Risk factors and resulting risk estimates could be used to complement remote clinical trials quality assurance strategies, and help to manage audit targets and audit focus also in post-pandemic times.Competing Interest StatementBjörn Koneswarakantha and Timothé Ménard were employed by Roche at the time this research was conducted.Funding StatementDevelopment of the statistical model was funded by Roche.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing is not applicable to this article as no datasets were generated or analysed during the current study. https://github.com/openpharma/quality_risk_assesment_clinical_trials ER -